Health Giants Reshape Industry Amid Surging Demand

Edwards Lifesciences is boosting its 2025 sales forecast due to robust demand for heart devices, pushing its shares up 8%. Meanwhile, Bavarian Nordic's potential takeover discussions have spurred a 24% surge in its stock, illustrating investor optimism. Such developments underscore major shifts in healthcare market dynamics.

Dr Reddy's Laboratories, eyeing a share in the $150 billion obesity drug market, plans to introduce a generic version of Novo Nordisk's weight-loss drug Wegovy across 87 countries next year. This decision marks an aggressive push by the Indian pharmaceutical firm into a lucrative and competitive field.

Giant corporations are navigating a complex regulatory landscape. With Novartis' billion-dollar investment in anti-inflammatory therapies and Roche exploring direct-to-consumer sales in the U.S., companies are strategically positioning themselves for future growth amid increasing pressure for affordable healthcare solutions.

(With inputs from agencies.)